Navigating a Changing Landscape in TNBC: Pharmacist-Focused Strategies in the Era of Immunotherapy

Activity Details
  • Credit Amounts:
    • CPE: 1.00
    • Other: 1.00
  • Cost: Free
  • Release: Apr 13, 2020
  • Expires: Apr 13, 2021
  • Estimated Time to Complete:
    1 Hour(s)
  • System Requirements:
  • Average User Rating:
    ( Ratings)


Sandra Cuellar Sandra Cuellar, PharmD, BCOP
University of Illinois Hospital & Health Sciences System
Chicago, Illinois

Rita Nanda Rita Nanda, MD
Director, Breast Oncology Program
The University of Chicago Medicine
Chicago, Illinois

Target Audience

This activity is designed to meet the educational needs of oncology pharmacists, pharmacy directors, and pharmacy residents.


At the conclusion of this application-based activity, participants will be able to:

  1. Discuss the molecular heterogeneity of triple-negative breast cancer (TNBC) and examine the diverse clinical features that impact treatment.
  2. Appraise the current state of the TNBC treatment paradigm and investigate emerging, top-line trial data regarding the safety and efficacy profiles of immune checkpoint inhibitors.
  3. Explore the importance of identifying novel biomarkers in TNBC to help guide treatment decisions.
  4. Using a case-based approach, evaluate clinical challenges in TNBC management and discuss adaptive ways the oncology pharmacist can optimize patient outcomes in the era of immunotherapy.



In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This application-based activity is approved for 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit (UAN JA0007101-0000-20-013-H01-P).

Creative Educational Concepts, Inc. certifies this activity for 1.00 hour of participation.

Faculty Disclosure

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.


Bryan Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.


Sandra Cuellar, PharmD, BCOP–has disclosed that she is on the speakers’ bureau for Eisai and Genentech.

Rita Nanda, MD–has disclosed that she is a consultant for Aduro, Clovis, Daiichi Sankyo, Inc., Genentech, MacroGenics, Merck, and Pfizer. She receives grant/research support from AstraZeneca, Celgene, Corcept Therapeutics, Genentech/Roche, Immunomedics, Merck, OBI Pharm, Inc., Odonate Therapeutics, Pfizer, and Seattle Genetics. She receives financial support from G1 Therapeutics (DSMB).

Content Reviewer:

Jason Bergsbaken, PharmD, BCOP–has no relevant financial relationships to disclose in relation to the content of this activity.


Presented by Creative Educational Concepts, Inc. (CEC) and supported through an independent educational grant from Merck & Co., Inc.